Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
DISHMAN PHARMA | GLENMARK PHARMA | DISHMAN PHARMA/ GLENMARK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 15.7 | 159.8% | View Chart |
P/BV | x | 3.3 | 2.6 | 129.8% | View Chart |
Dividend Yield | % | 0.7 | 0.4 | 170.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
GLENMARK PHARMA Mar-19 |
DISHMAN PHARMA/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 712 | 52.6% | |
Low | Rs | 129 | 484 | 26.7% | |
Sales per share (Unadj.) | Rs | 197.8 | 349.6 | 56.6% | |
Earnings per share (Unadj.) | Rs | 21.2 | 32.8 | 64.7% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 44.3 | 78.3% | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 100.0% | |
Dividend yield (eoy) | % | 0.8 | 0.3 | 237.5% | |
Book value per share (Unadj.) | Rs | 179.9 | 198.6 | 90.6% | |
Shares outstanding (eoy) | m | 80.69 | 282.17 | 28.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 1.7 | 74.4% | |
Avg P/E ratio | x | 11.9 | 18.2 | 65.1% | |
P/CF ratio (eoy) | x | 7.2 | 13.5 | 53.8% | |
Price / Book Value ratio | x | 1.4 | 3.0 | 46.5% | |
Dividend payout | % | 9.4 | 6.1 | 154.6% | |
Avg Mkt Cap | Rs m | 20,306 | 168,625 | 12.0% | |
No. of employees | `000 | 0.8 | 12.0 | 6.9% | |
Total wages/salary | Rs m | 5,355 | 20,561 | 26.0% | |
Avg. sales/employee | Rs Th | 19,252.7 | 8,196.0 | 234.9% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,708.1 | 378.2% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 768.5 | 268.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 98,655 | 16.2% | |
Other income | Rs m | 265 | 2,081 | 12.8% | |
Total revenues | Rs m | 16,226 | 100,736 | 16.1% | |
Gross profit | Rs m | 4,103 | 15,858 | 25.9% | |
Depreciation | Rs m | 1,091 | 3,259 | 33.5% | |
Interest | Rs m | 944 | 3,346 | 28.2% | |
Profit before tax | Rs m | 2,334 | 11,335 | 20.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
Tax | Rs m | 624 | 3,756 | 16.6% | |
Profit after tax | Rs m | 1,711 | 9,250 | 18.5% | |
Gross profit margin | % | 25.7 | 16.1 | 159.9% | |
Effective tax rate | % | 26.7 | 33.1 | 80.6% | |
Net profit margin | % | 10.7 | 9.4 | 114.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 66,968 | 16.5% | |
Current liabilities | Rs m | 9,517 | 40,211 | 23.7% | |
Net working cap to sales | % | 9.4 | 27.1 | 34.7% | |
Current ratio | x | 1.2 | 1.7 | 69.5% | |
Inventory Days | Days | 110 | 83 | 132.6% | |
Debtors Days | Days | 35 | 81 | 42.9% | |
Net fixed assets | Rs m | 16,304 | 33,322 | 48.9% | |
Share capital | Rs m | 161 | 282 | 57.2% | |
"Free" reserves | Rs m | 12,907 | 55,770 | 23.1% | |
Net worth | Rs m | 14,516 | 56,052 | 25.9% | |
Long term debt | Rs m | 4,189 | 35,738 | 11.7% | |
Total assets | Rs m | 29,805 | 132,888 | 22.4% | |
Interest coverage | x | 3.5 | 4.4 | 79.1% | |
Debt to equity ratio | x | 0.3 | 0.6 | 45.3% | |
Sales to assets ratio | x | 0.5 | 0.7 | 72.1% | |
Return on assets | % | 8.9 | 9.5 | 94.0% | |
Return on equity | % | 11.8 | 16.5 | 71.4% | |
Return on capital | % | 17.5 | 17.8 | 98.4% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 62,998 | 7.9% | |
Fx outflow | Rs m | 697 | 22,859 | 3.0% | |
Net fx | Rs m | 4,255 | 40,140 | 10.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 13,242 | 21.0% | |
From Investments | Rs m | -1,529 | -6,990 | 21.9% | |
From Financial Activity | Rs m | -941 | -7,387 | 12.7% | |
Net Cashflow | Rs m | 316 | -2,971 | -10.7% |
Indian Promoters | % | 61.4 | 48.3 | 127.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 6.9 | 53.6% | |
FIIs | % | 12.7 | 34.4 | 36.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 10.5 | 210.5% | |
Shareholders | 46,261 | 56,727 | 81.6% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: UNICHEM LAB AUROBINDO PHARMA STERLING BIOTECH WOCKHARDT SUN PHARMA
Compare DISHMAN PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.
For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More